TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22884662

Group type: EXPERIMENTAL
Intervention: Two vaccinations with Vero cell-derived whole virus non-adjuvanted H5N1 vaccine (7.5 μg HA Antigen A/Vietnam/1203/2004)
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Booster vaccinations at 6, 12-15, and 24 months with 7.5 μg A/Indonesia/05/2005
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Booster vaccinations with 3.75 μg A/Indonesia/05/2005
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Single dose priming with 7.5 μg A/Vietnam/1203/2004 followed by a 12 month booster (7.5 μg)
Number of subjects: 561
Study: 20418697

Group type: EXPERIMENTAL
Intervention: Spanish version of the SF-8 health-related quality-of-life questionnaire administered before surgery and again 3 months later.
Number of subjects: 2991

Group type: EXPERIMENTAL
Intervention: Spanish version of the SF-8 health-related quality-of-life questionnaire administered before surgery.
Number of subjects: 2991

Group type: EXPERIMENTAL
Intervention: Spanish version of the SF-8 health-related quality-of-life questionnaire administered after surgery.
Number of subjects: 2991

Group type: EXPERIMENTAL
Intervention: Spanish version of the SF-8 health-related quality-of-life questionnaire administered to women.
Number of subjects: 2991
Study: 18405411

Group type: EXPERIMENTAL
Intervention: Rocuronium (0.6 mg kg‐1)
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Cisatracurium (0.1 mg kg‐1)
Number of subjects: 848
Study: 15747810

Group type: EXPERIMENTAL
Intervention: Mandible-protruding oral appliance
Number of subjects: 14
Study: 12803833

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 45
Study: 10337858

Group type: EXPERIMENTAL
Intervention: GHRP-2
Number of subjects: 8

Group type: COMPARATOR
Intervention: Arginine
Number of subjects: 8
Study: 7861016

Group type: EXPERIMENTAL
Intervention: Stavudine 20 mg twice daily for patients > or = 60 kg
Number of subjects: 8127

Group type: EXPERIMENTAL
Intervention: Stavudine 40 mg twice daily for patients > or = 60 kg
Number of subjects: 8127

Group type: EXPERIMENTAL
Intervention: Stavudine 15 mg twice daily for patients weighing 40-59 kg
Number of subjects: 8127

Group type: EXPERIMENTAL
Intervention: Stavudine 30 mg twice daily for patients weighing 40-59 kg
Number of subjects: 8127

Group type: EXPERIMENTAL
Intervention: Stavudine 10 mg twice daily for patients weighing < 40 kg
Number of subjects: 8127

Group type: EXPERIMENTAL
Intervention: Stavudine 20 mg twice daily for patients weighing < 40 kg
Number of subjects: 8127
Study: 2015169

Group type: EXPERIMENTAL
Intervention: 100 mg flosequinan
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 200 mg flosequinan
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 7129331

Group type: EXPERIMENTAL
Intervention: 10 mg nifedipine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 20 mg nifedipine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 30 mg nifedipine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30762756

Group type: EXPERIMENTAL
Intervention: Active children with asthma
Number of subjects: 192

Group type: COMPARATOR
Intervention: Active healthy children
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Inactive children with asthma
Number of subjects: 192

Group type: COMPARATOR
Intervention: Inactive healthy children
Number of subjects: 192
Study: 27917567

Group type: EXPERIMENTAL
Intervention: 2% arginine bicarbonate
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 1% urea
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 0.05% NaF solution
Number of subjects: 14

Group type: COMPARATOR
Intervention: water
Number of subjects: 14
Study: 25535772

Group type: EXPERIMENTAL
Intervention: Unilateral lobe resection via video-assisted thoracoscopy (VATS)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Unilateral sublobe resection via video-assisted thoracoscopy (VATS)
Number of subjects: 36
Study: 24548981

Group type: EXPERIMENTAL
Intervention: Mipomersen 50 mg SC
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mipomersen 100 mg SC
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mipomersen 200 mg SC
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 23073811

Group type: EXPERIMENTAL
Intervention: Micro-implant group
Number of subjects: 20

Group type: COMPARATOR
Intervention: J-hook headgear group
Number of subjects: 20
Study: 19526757

Group type: EXPERIMENTAL
Intervention: Chaiqin Chengqi Decoction (CQCQD) administered immediately after hospitalization (early-treated group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional Western medical therapy (same for both groups)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chaiqin Chengqi Decoction (CQCQD) administered 3 days after hospitalization (late-treated group)
Number of subjects: 40
Study: 17296341

Group type: EXPERIMENTAL
Intervention: Rimonabant 5 mg once daily
Number of subjects: 1047

Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg once daily
Number of subjects: 1047

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1047
Study: 15155394

Group type: EXPERIMENTAL
Intervention: Webster-Stratton Parents and Children Series group parenting programme
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 116
Study: 11681436

Group type: EXPERIMENTAL
Intervention: Quantitative culture of the subcutaneous catheter segment using roll-plate and sonication methods
Number of subjects: 479

Group type: COMPARATOR
Intervention: Semiquantitative and quantitative catheter-tip cultures
Number of subjects: 479
Study: 10216370

Group type: EXPERIMENTAL
Intervention: Antirejection therapy for Group I (10 patients) for 7 days
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Antimicrobial therapy for Group II (20 patients) for 2 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Asymptomatic bacteriuria (Group II)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Acute pyelonephritis (Group II)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Patients with stable renal function (control group)
Number of subjects: 50
Study: 7523479

Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies to LH
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Highly purified pituitary LH and immunoaffinity purified urinary LH
Number of subjects: 300

Group type: COMPARATOR
Intervention: Commercially available LH assay kits
Number of subjects: 300
Study: 3243014

Group type: EXPERIMENTAL
Intervention: Unilateral grommet insertion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lighter grommet (hypothetical consideration)
Number of subjects: 0
Study: 31403944

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (AET)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Stretching and toning (SAT)
Number of subjects: 70
Study: 28365225

Group type: EXPERIMENTAL
Intervention: Two-dose regimen at 0 and 3 months (group 1)
Number of subjects: 1794

Group type: EXPERIMENTAL
Intervention: One dose at 0 months (group 2)
Number of subjects: 1794

Group type: EXPERIMENTAL
Intervention: One dose at 0 months and a booster at 12 months (group 3)
Number of subjects: 1794

Group type: COMPARATOR
Intervention: Placebo (group 4)
Number of subjects: 1794
Study: 25473078

Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitor (PPI) for 8 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Revaprazan for 8 weeks
Number of subjects: 26
Study: 22543270

Group type: EXPERIMENTAL
Intervention: Positive relationship experiences
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Negative couple interactions
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Positive couple interactions
Number of subjects: 180
Study: 21175344

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0
Study: 19696363

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no HRT)
Number of subjects: 14
Study: 18399039

Group type: EXPERIMENTAL
Intervention: Fluoxetine and cognitive therapy (CT)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Fluoxetine and interpersonal therapy (IPT)
Number of subjects: 35
Study: 15472659

Group type: EXPERIMENTAL
Intervention: Short-term nonsteroidal anti-inflammatory drugs and self-care instructions (palliative care group)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drugs, self-care instructions, and occlusal appliance and mobilization therapy (physical medicine group)
Number of subjects: 69

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 69
Study: 11868057

Group type: EXPERIMENTAL
Intervention: Primary percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conservative no-PTCA group
Number of subjects: 120
Study: 9670410

Group type: EXPERIMENTAL
Intervention: gamma interferon (gamma-IFN)
Number of subjects: 128

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 128
Study: 7924541

Group type: EXPERIMENTAL
Intervention: Nonpharmacologic therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 2507061

Group type: EXPERIMENTAL
Intervention: Captopril (25‐100 mg/day for 12 months, average dose 40 mg daily during the second six months)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 32
Study: 780037

Group type: EXPERIMENTAL
Intervention: Oxprenolol 20 mg three times daily, increased to 40 and 80 mg if SDP exceeded 89 mm Hg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Propranolol 20 mg three times daily, increased to 40 and 80 mg if SDP exceeded 89 mm Hg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Both oxprenolol and propranolol
Number of subjects: 26
Study: 31278705

Group type: EXPERIMENTAL
Intervention: Intra-articular NSAID Ketorolac injection
Number of subjects: 160

Group type: COMPARATOR
Intervention: Intra-articular Hyaluronic acid injection
Number of subjects: 160
Study: 28489735

Group type: EXPERIMENTAL
Intervention: Conversational hypnosis session
Number of subjects: 97

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 97
Study: 24832381

Group type: EXPERIMENTAL
Intervention: H. pylori treatment group (n=11)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Non-intervention control group (n=11)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Non-treated controls (n=13) after 6-12 months of follow-up
Number of subjects: 85

Group type: COMPARATOR
Intervention: Uninfected patients (n=58)
Number of subjects: 85
Study: 24050956

Group type: EXPERIMENTAL
Intervention: Talactoferrin (1.5 g p.o. BID)
Number of subjects: 742

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 742
Study: 21282040

Group type: EXPERIMENTAL
Intervention: Biomimetic hydroxyapatite (HA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nanocrystalline hydroxyapatite (HA)
Number of subjects: 10
Study: 19815148

Group type: EXPERIMENTAL
Intervention: Light buccally directed orthodontic force of 25 g
Number of subjects: 10

Group type: COMPARATOR
Intervention: Heavy orthodontic force of 225 g
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Maxillary first premolars
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Buccal surface
Number of subjects: 10
Study: 18693591

Group type: EXPERIMENTAL
Intervention: Calcium Acetate
Number of subjects: 64

Group type: COMPARATOR
Intervention: Calcium Carbonate
Number of subjects: 64
Study: 15328177

Group type: EXPERIMENTAL
Intervention: Ep-CAM protein (400 microg/dose)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Anti-Id antibody (500 microg/dose)
Number of subjects: 13
Study: 11210403

Group type: EXPERIMENTAL
Intervention: Oxycodone, 5 mg p.o. Q4H and levofloxacin, 500 mg p.o. 1 hour after starting oxycodone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Levofloxacin, 500 mg p.o. alone
Number of subjects: 8
Study: 9468210

Group type: EXPERIMENTAL
Intervention: Vitamin C (25 mg/min IA)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Vitamin C (oral therapy for 4 weeks)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Vitamin C (acute treatment)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Vitamin C (chronic treatment)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 8050539

Group type: EXPERIMENTAL
Intervention: UPPP
Number of subjects: 155

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 155
Study: 2479252

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 100 mg daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1960

Group type: EXPERIMENTAL
Intervention: 200 mug beclomethasone dipropionate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 300 mug beclomethasone dipropionate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 400 mug beclomethasone dipropionate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 28796130

Group type: EXPERIMENTAL
Intervention: Alternate Peripheral (A-P) superset configuration
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Similar Biomechanical (SB) superset configuration
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All superset protocols
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Agonist-Antagonist (A-A) superset configuration
Number of subjects: 10
Study: 31622033

Group type: EXPERIMENTAL
Intervention: Social media-based, health literacy-sensitive diabetes management intervention
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Telephone-based, health literacy-sensitive diabetes management intervention
Number of subjects: 151

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Social media-based intervention
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Telephone-based intervention
Number of subjects: 151
Study: 28116151

Group type: EXPERIMENTAL
Intervention: Objective MVPA (≥3 METs and ≥10 min)
Number of subjects: 595

Group type: COMPARATOR
Intervention: Self-report MVPA
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Objective SB (<1.5 METs)
Number of subjects: 595

Group type: COMPARATOR
Intervention: Subjective SB
Number of subjects: 595
Study: 26722513

Group type: EXPERIMENTAL
Intervention: Combined therapy (chemotherapy plus DC/CIK immunotherapy)
Number of subjects: 50
Study: 23752288

Group type: EXPERIMENTAL
Intervention: P4HB sutures
Number of subjects: 22

Group type: COMPARATOR
Intervention: Polyglactin 910 sutures
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Visual analog scale and Hollander Wound Evaluation Scale
Number of subjects: 22
Study: 21378634

Group type: EXPERIMENTAL
Intervention: Warm skin disinfection (38°C)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cold skin disinfection (20°C)
Number of subjects: 10
Study: 19073787

Group type: EXPERIMENTAL
Intervention: Rosiglitazone, 3 mg/m²/d for 16 weeks
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 11
Study: 17042890

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) as an adjunct to pharmacological treatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: No psychosocial intervention (Control)
Number of subjects: 8
Study: 15930482

Group type: EXPERIMENTAL
Intervention: Choline supplementation
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Carnitine supplementation
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Choline and Carnitine supplementation
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 19
Study: 12795789

Group type: EXPERIMENTAL
Intervention: Er:YAG laser irradiation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hand instrumentation (scaling and root planing - SRP)
Number of subjects: 30
Study: 10513801

Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 0
Study: 8588058

Group type: COMPARATOR
Intervention: Trimipramine alone 200 mg/d (group 1)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Trimipramine (200 mg/d) and additional serial partial sleep deprivation (3x/week) (group 2)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (group 1)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Experimental (group 2)
Number of subjects: 18
Study: 2048453

Group type: EXPERIMENTAL
Intervention: Nicotine gum (before or after drinking)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sugarless gum (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol (after chewing gum)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotine gum (side effects)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Demographic and historical variables
Number of subjects: 0
Study: 6165205

Group type: EXPERIMENTAL
Intervention: 0.025% budesonide ointment
Number of subjects: 116

Group type: COMPARATOR
Intervention: 0.025% fluocinolone acetonide ointment
Number of subjects: 116

Group type: COMPARATOR
Intervention: 0.010% budesonide ointment
Number of subjects: 116
Study: 31747132

Group type: EXPERIMENTAL
Intervention: SGLT-2 inhibitors (empagliflozin and canagliflozin)
Number of subjects: 139317

Group type: EXPERIMENTAL
Intervention: FDA-eligible patients
Number of subjects: 139317
Study: 30111333

Group type: EXPERIMENTAL
Intervention: F@ce™ intervention (8-week family-centred intervention with goal setting, problem-solving strategies, daily reminders, and self-rated follow-ups via SMS)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 28
Study: 27394383

Group type: EXPERIMENTAL
Intervention: COPE intervention (10 in-home occupational therapy visits, 1 in-home visit, and 1 telephone contact by an advanced practice nurse)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: COPE intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ongoing CHCPE services only
Number of subjects: 0
Study: 23942200

Group type: EXPERIMENTAL
Intervention: Genetics e‐learning Continuing Professional Development (CPD) module
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80
Study: 27552780

Group type: EXPERIMENTAL
Intervention: Email plus text messaging for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Email only
Number of subjects: 0
Study: 19484170

Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg once weekly for 8 weeks
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 18787216

Group type: EXPERIMENTAL
Intervention: Linezolid (600 mg twice daily)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Linezolid (600 mg once daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isoniazid (300 mg daily)
Number of subjects: 30
Study: 16234222

Group type: EXPERIMENTAL
Intervention: Intense exercise
Number of subjects: 28

Group type: COMPARATOR
Intervention: No exercise
Number of subjects: 28
Study: 14507557

Group type: EXPERIMENTAL
Intervention: Tracheoscopy
Number of subjects: 26
Study: 12119985

Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8884013

Group type: EXPERIMENTAL
Intervention: Honey dressing
Number of subjects: 100

Group type: COMPARATOR
Intervention: Boiled potato peel dressing
Number of subjects: 100
Study: 1395117

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0
Study: 3878441

Group type: EXPERIMENTAL
Intervention: Tolfenamic acid alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tolfenamic acid with caffeine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tolfenamic acid with placebo
Number of subjects: 0
Study: 29175066

Group type: EXPERIMENTAL
Intervention: EmbryoScope (TLI)
Number of subjects: 386

Group type: COMPARATOR
Intervention: G185 K-System (G185)
Number of subjects: 386
Study: 27569734

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Remifentanil plus midazolam
Number of subjects: 99

Group type: COMPARATOR
Intervention: Meperidine/midazolam
Number of subjects: 99
Study: 24690891

Group type: EXPERIMENTAL
Intervention: Tidal volume of 4 ml/kg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Tidal volume of 6 ml/kg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Tidal volume of 8 ml/kg
Number of subjects: 39

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 39
Study: 22417569

Group type: EXPERIMENTAL
Intervention: Heated and humidified high-flow oxygen therapy (HHFO₂)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard oxygen therapy (no humidification)
Number of subjects: 30
Study: 20618242

Group type: EXPERIMENTAL
Intervention: Vacca Re‐Usable Omnicup
Number of subjects: 200

Group type: COMPARATOR
Intervention: Bird anterior and posterior metal cups
Number of subjects: 200
Study: 18762033

Group type: EXPERIMENTAL
Intervention: Resin cement (2bond2)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Glass ionomer cement (Ketac Cem)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Occlusal thickness of 0.5 mm
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Occlusal thickness of 1.3 mm
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Chamfer finish line
Number of subjects: 128

Group type: COMPARATOR
Intervention: Shoulder finish line
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Total convergence angle of 4 degrees
Number of subjects: 128

Group type: COMPARATOR
Intervention: Total convergence angle of 11 degrees
Number of subjects: 128
Study: 15800921

Group type: COMPARATOR
Intervention: Low-fat, high-fiber diet (LFHF)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Soy supplement with isoflavones (soy+IF)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Soy supplement (both soy+IF and soy-IF)
Number of subjects: 154
Study: 12867777

Group type: EXPERIMENTAL
Intervention: Chronic Heart Failure Questionnaire (CHQ)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Minnesota Living with Heart Failure Questionnaire (LHFQ)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: General Health Survey Short-form-12 (SF-12)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Face-to-face interviews
Number of subjects: 211

Group type: COMPARATOR
Intervention: Telephone interviews
Number of subjects: 211